Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas , N Engl J Med, 377(26): 2017,2545-2554
Jakub Svoboda, Steven M Bair, Daniel J Landsburg, Sunita Dwivedy Nasta, Sarah J Nagle, Stefan K Barta, Nadia Khan, Joanne Filicko-O'Hara, Sameh Gaballa, Lauren Strelec, Elise Chong, Sheryl Mitnick, Terease S Waite, Cara King, Hatcher Ballard, Matthew Youngman, James Gerson, John P Plastaras, Amit Maity, Agata M Bogusz, Stacy S Hung, Hisae Nakamura, Reza Nejati, Christian Steidl, Megan Lim, Marco Ruella, Stephen J Schuster Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas , Haematologica, 106(6): 2021,1705 -1713
Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, Suhoski MM, Melenhorst JJ, Loudon B, Mato AR, Nasta SD, Landsburg DJ, Youngman MR, Levine BL, Porter DL, June CH, Schuster SJ. Non-viral RNA chimeric antigen receptor modified T cells in patients with Hodgkin lymphoma. , Blood, 132(10): 2018,1022-1026
Ruan J1, Martin P1, Christos P2, Cerchietti L1, Tam W3, Shah B4, Schuster SJ5, Rodriguez A1, Hyman D1, Calvo-Vidal MN1, Smith SM6, Svoboda J4, Furman RR1, Coleman M1, Leonard JP1. Five-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma. , Blood, 132(19): 2018,2016-2025
P Armand, S Rodig, V Melnichenko, C Thieblemont, K Bouabdallah, G Tumyan, M Özcan, S Portino, L Fogliatto, MD Caballero, J Walewski, Z Gulbas, V Ribrag, B Christian, GF Perini, G Salles, J Svoboda, J Zain, S Patel, PH Chen, AH Ligon, J Ouyang, D Neuberg, R Redd, A Chatterjee, A Balakumaran, R Orlowski, M Shipp, and PL Zinzani Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma , J Clin Oncol., 37(34): 2019,3291-3299
Bair SM, Mato A, Svoboda J. Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm. , Clin Lymphoma Myeloma Leuk, 18(6): 2018,380-391
Elise A Chong, Cécile Alanio, Jakub Svoboda, Sunita D Nasta, Daniel J Landsburg, Simon F Lacey, Marco Ruella, Siddharth Bhattacharyya, E John Wherry, Stephen J Schuster Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy , Blood, The Journal of the American Society of Hematology, 139(7): 2022,1026-1038
G Ghilardi, EA Chong, J Svoboda, P Wohlfarth, SD Nasta, S Williamson, JD Landsburg, JN Gerson, SK Barta, R Pajarillo, J Myers, AI Chen, L Schachter, R Yelton, HJ Ballard, A Hodges Dwinal, S Gier, D Victoriano, E Weber, E Napier, A Garfall, DL Porter, U Jäger, RT Maziarz, M Ruella, SJ Schuster Bendamustine is Safe and Effective for Lymphodepletion Before Tisagenlecleucel in Patients with Refractory or Relapsed Large B-Cell Lymphomas , Annals of Oncology: 2022
Miguel-Angel Perales, Larry D Anderson Jr, Tania Jain, Saad S Kenderian, Olalekan O Oluwole, Gunjan L Shah, Jakub Svoboda, Mehdi Hamadani Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy , Transplantation and Cellular Therapy , 28(9): 2022,546-559
Carrie Ho, Marco Ruella, Bruce L Levine, Jakub Svoboda Adoptive T-cell therapy for Hodgkin lymphoma , Blood Advances, 5(20): 2021,4291-4302
